By 2030, 1 in 6 people globally will be 60 years or older1 . As global life expectancies continue to increase, so do cases of dementia. While the recent availability of anti-amyloid therapies has changed patient management strategies, advancements in high-sensitivity immunoassay platforms have paved the way for a new era in the evaluation of Alzheimer’s disease. Because of these breakthroughs, blood-based biomarkers can now be effective tools in the assessments of individuals with symptoms of cognitive impairment.
In the context of all clinical findings in individuals presenting with cognitive impairment, the pTau-217/Beta Amyloid 42 Ratio can aid in the identification of amyloid-related pathology, which is associated with Alzheimer’s disease. This test is not intended as a screening test for Alzheimer’s disease in asymptomatic individuals.
Substantially equivalent performance to FDA-cleared cerebrospinal fluid (CSF) assays and positron emission topography (PET) imaging
Highly sensitive and specific test: Sensitivity = 95%, Specificity = 95%
Widely covered by third party payers
| Triage Test | Confirmatory Test | |
|---|---|---|
| Global CEOi performance criteria* | Sensitivity ≥90% Specificity ≥ 75–85%, depending on capacity for follow-up amyloid PET or CSF testing For a test with two cutoffs, <20% of individuals should have an intermediate result | Sensitivity ≥90% Specificity ≥90% For a test with two cutoffs, <20% of individuals should have an intermediate result |
| Labcorp test performance |
Sensitivity: 95% Specificity: 84% Beta-Amyloid 42/40 Ratio (505725) Sensitivity: 96% Specificity: 87%) | pTau-217/Beta Amyloid 42 Ratio (505415) Sensitivity: 95% Specificity: 95% |
Assay sensitivity and specificity is dependent on pathological characteristics of study cohort
Discover how our ATN Profile can help accelerate the path to Alzheimer’s diagnosis.
Labcorp is leading in Alzheimer’s disease testing with the largest portfolio of blood biomarker options from a single diagnostic provider.
?fmt=webp)
How Labcorp’s leadership in Alzheimer’s disease testing is guiding work in other neurological diseases
Contact a Labcorp representative to learn more about how we can help meet your neurology testing needs
